Alvarez & Marsal has been appointed as joint administrators of TC BioPharm Limited, a clinical-stage cell therapy company, following the company’s entry into administration on 2 October 2025. The administrators have launched a sale process for the business and assets, including intellectual property.

TC BioPharm is an early developer of allogeneic Gamma-Delta T-cell therapies and was the first company to conduct Phase II clinical studies of these cells in patients with acute myeloid leukemia (AML). The company operates from an R&D facility in Motherwell, Scotland, and employs a small team of scientists supported by experienced leadership with connections across the US and Europe.

Michael Magnay, joint administrator at Alvarez & Marsal, said: “TC BioPharm is a pioneering, clinical-stage cell therapy company with an experienced and highly skilled team. As Joint Administrators, our priority is to run a sale process at pace, and we encourage any parties interested in acquiring the business and assets, which include the intellectual property, to reach out to us as soon as possible.”

No immediate redundancies are planned as the administrators conduct the sale process. The move offers an opportunity for other companies or investors to acquire TC BioPharm’s technology, team, and ongoing programs in Gamma-Delta T-cell therapy for AML.